NCT04543188: A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Breast cancer patients are eligible for the dose expansion (Part B, Cohort 5 or 6 of the study); Patients must have documented evidence of a BRAF V600 mutation in tumor tissue or blood
Exclusions: Patients with brain metastasis requiring immediate local intervention (e.g. radiation therapy or surgery); Patients with history of or current leptomeningeal metastases

Comments are closed.

Up ↑